Chapter 17 Cytokines and pain

Handbook of Clinical Neurology

Volumn 81, Issue , 2006, Pages 231-248

  Sommer, Claudia ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649333449     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(06)80021-7     Document Type: Article

References (255)

1. Abbadie C., Lindia J.A., Cumiskey A.M., Peterson L.B., Mudgett J.S., Bayne E.K., DeMartino J.A., MacIntyre D.E., and Forrest M.J. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci USA 100 (2003) 7947-7952
2. Aggarwal B.B., and Natarajan K. Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw 7 (1996) 93-124
3. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Natl Rev Immunol 3 (2003) 745-756
4. Ahn S.H., Cho Y.W., Ahn M.W., Jang S.H., Sohn Y.K., and Kim H.S. mRNA expression of cytokines and chemokines in herniated lumbar intervertebral discs. Spine 27 (2002) 911-917
5. discussion 1066. Alstergren P., Ernberg M., Kvarnstrom M., and Kopp S. Interleukin-1beta in synovial fluid from the arthritic temporomandibular joint and its relation to pain, mobility, and anterior open bite. J Oral Maxillofac Surg 56 (1998) 1059-1065
6. Amel Kashipaz M.R., Swinden D., Todd I., and Powell R.J. Normal production of inflammatory cytokines in chronic fatigue and fibromyalgia syndromes determined by intracellular cytokine staining in short-termcultured blood mononuclear cells. Clin Exp Immunol 132 (2003) 360-365
7. Aoki Y., Rydevik B., Kikuchi S., and Olmarker K. Local application of disc-related cytokines on spinal nerve roots. Spine 27 (2002) 1614-1617
8. Appay V., and Rowland-Jones S.L. RANTES: a versatile and controversial chemokine. Trends Immunol 22 (2001) 83-87
9. Arruda J.L., Sweitzer S., Rutkowski M.D., and DeLeo J.A. Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic p. Brain Res 879 (2000) 216-225
10. Atcheson S.G., and Dymeck T. Rapid resolution of chronic sciatica with intravenous infliximab after failed epidural steroid injections. Spine 29 (2004) E248-E250
11. Banks R.E., Forbes M.A., Storr M., Higginson J., Thompson D., Raynes J., Illingworth J.M., Perren T.J., Selby P.J., and Whicher J.T. The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol 102 (1995) 217-223
12. Banks R.E., Forbes M.A., Patel P.M., Storr M., Hallam S., Clarke D., Novick D., Ingham E., Bowmer C., Southgate J., Trejdosiewicz L.K., Illingworth J., Perren T.J., and Selby P.J. Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics andimmunomodulatory effects. Cytokine 12 (2000) 388-396
13. Barnes P.F., Chatterjee D., Brennan P.J., Rea T.H., and Modlin R.L. Tumor necrosis factor production in patients with leprosy. Infec Immun 60 (1992) 1441-1446
14. Beattie E.C., Stellwagen D., Morishita W., Bresnahan J.C., Ha B.K., Von Zastrow M., Beattie M.S., and Malenka R.C. Control of synaptic strength by glial TNFalpha. Science 295 (2002) 2282-2285
15. Bianchi M., Sacerdote P., Ricciardi-Castagnoli P., Mantegazza P., and Panerai A. Central effects of tumor necrosis factor and interleukin-1alpha on nociceptive thresholds and spontaneous locomotor activity. Neurosci Lett 148 (1992) 76-80
16. Bianchi M., Maggi R., Pimpinelli F., Rubino T., Parolaro D., Poli V., Ciliberto G., Panerai A.E., and Sacerdote P. Presence of a reduced opioid response in interleukin-6 knock out mice. Eur J Neurosci 11 (1999) 1501-1507
17. Bolin L.M., Murray R., Lukacs N.W., Strieter R.M., Kunkel S.L., Schall T.J., and Bacon K.B. Primary sensory neurons migrate in response to the chemokine RANTES. J Neuroimmunol 81 (1998) 49-57
18. Bourde O., Kiefer R., Toyka K.V., and Hartung H.P. Quantification of interleukin-6 mRNA in Wallerian degeneration by competitive reverse transcription polymerase chain reaction. J Neuroimmunol 69 (1996) 135-140
19. Brisby H., Olmarker K., Larsson K., Nutu M., and Rydevik B. Proinflammatory cytokines in cerebrospinal fluid and serum in patients with disc herniation and sciatica. Eur Spine J 11 (2002) 62-66
20. Brodie C., Goldreich N., Haiman T., and Kazimirsky G. Functional IL-4 receptors on mouse astrocytes: IL-4 inhibits astrocyte activation and induces NGF secretion. J Neuroimmunol 81 (1998) 20-30
21. Burke J.G., Watson R.W., McCormack D., Dowling F.E., Walsh M.G., and Fitzpatrick J.M. Spontaneous production of monocyte chemoattractant protein-1 and interleukin-8 by the human lumbar intervertebral disc. Spine 27 (2002) 1402-1407
22. Chao C.C., Molitor T.W., and Hu S. Neuroprotective role of IL-4 against activated microglia. J Immunol 151 (1993) 1473-1481
23. RC87. Chapman G.A., Moores K., Harrison D., Campbell C.A., Stewart B.R., and Strijbos P.J. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci 20 (2000)
24. Chapman P.B., Lester T.J., Casper E.S., Gabrilove J.L., Wong G.Y., Kempin S.J., Gold P.J., Welt S., Warren R.S., and Starnes H.F. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 5 (1987) 1942-1951
25. Ching D.W.T., McClintock A., and Beswick F. Successful treatment with low-dose thalidomide in a patient with both Behçet's disease and complex regional pain syndrome type I. J Clin Rheumatol 9 (2003) 96-98
26. Cohen S.B., Moreland L.W., Cush J.J., Greenwald M.W., Block S., Shergy W.J., Hanrahan P.S., Kraishi M.M., Patel A., Sun G., and Bear M.B. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patientswith rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63 (2004) 1062-1068
27. Cooper R.G., and Freemont A.J. TNF-alpha blockade for herniated intervertebral disc-induced sciatica: a way forward at last?. Rheumatology (Oxford) 43 (2004) 119-121
28. Covelli V., Munno I., Pellegrino N.M., Di Venere A., Jirillo E., and Buscaino G.A. Exaggerated spontaneous release of tumor necrosis factor-alpha/cachectin in patients with migraine without aura. Acta Neurol (Napoli) 2 (1990) 257-263
29. Covelli V., Munno I., Pellegrino N.M., Altamura M., Decandia P., Marcuccio C., Di Venere A., and Jirillo E. Are TNF-alpha and IL-1 beta relevant in the pathogenesis of migraine without aura?. Acta Neurol (Napoli) 13 (1991) 205-211
30. Covelli V., Munno I., Pellegrino N.M., Marinaro M.R., Gesario A., Massari F., Savastano S., and Jirillo E. In vivo administration of propranolol decreases exaggerated amounts of serum TNF-alpha in patients with migraine without aura. Possible mechanism ofaction. Acta Neurol (Napoli) 14 (1992) 313-319
31. Covey W.C., Ignatowski T.A., Knight P.R., and Spengler R.N. Brain-derived TNFalpha: involvement in neuroplastic changes implicated in the conscious perception of persistent pain. Brain Res 859 (2000) 113-122
32. Creaven P.J., Plager J.E., Dupere S., Huben R.P., Takita H., Mittelman A., and Proefrock A. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 20 (1987) 137-144
33. Cunha F., Poole S., Lorenzetti B., and Ferreira S. The pivotal role of tumor necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol 107 (1992) 660-664
34. Cunha F.Q., Lorenzetti B.B., Poole S., and Ferreira S.H. Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol 107 (1991) 165-167
35. Cunha F.Q., Poole S., Lorenzetti B.B., Veiga F.H., and Ferreira S.H. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4. Br J Pharmacol 126 (1999) 45-50
36. Cunha J.M., Cunha F.Q., Poole S., and Ferreira S.H. Cytokinemediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br J Pharmacol 130 (2000) 1418-1424
37. Czlonkowski A., Stein C., and Herz A. Peripheral mechanisms of opioid antinociception in inflammation: involvement of cytokines. Eur J Pharmacol 242 (1993) 229-235.
38. Davis A.J., and Perkins M.N. The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat. Br J Pharmacol 113 (1994) 63-68
39. Dayer J.M., and Demczuk S. Cytokines and other mediators in rheumatoid arthritis. Springer Semin Immunopathol 7 (1984) 387-413
40. DeLeo J.A., Rutkowski M.D., Stalder A.K., and Campbell I.L. Transgenic expression of TNF by astrocytes increases mechanical allodynia in a mouse neuropathy model. Neuroreport 11 (2000) 599-602
41. DeLeo J.A., and Yezierski R.P. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90 (2001) 1-6
42. DeLeo J.A., Tanga F.Y., and Tawfik V.L. Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist 10 (2004) 40-52
43. Del Mastro L., Venturini M., Giannessi P.G., Vigani A., Garrone O., Carnino F., Russo P., Galletti P., Rosso R., and Conte P.F. Intraperitoneal infusion of recombinant human tumor necrosis factor and mitoxantrone in neoplastic ascites: a feasibility study. Anticancer Res 15 (1995) 2207-2212
44. Diem R., Meyer R., Weishaupt J.H., and Bahr M. Reduction of potassium currents and phosphatidylinositol 3-kinase-dependent AKT phosphorylation by tumor necrosis factor-(alpha) rescues axotomizedretinal ganglion cells from retrograde cell death in vivo. J Neurosci 21 (2001) 2058-2066
45. Dinarello C. Interleukin-1 and interleukin-1 antagonism. Blood 77 (1991) 1627-1652
46. Dinarello C.A. Overview of inflammatory cytokines and their role in pain. In: Walkins L.R., and Maier S.F. (Eds). Cytokines and Pain (1999), Birkhäuser, Basel 1-19
47. Dinarello C.A. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 4 (2004) 378-385
48. Ding Y., Fu S., Zamarin D., and Bromberg J. Interleukin-10. In: Thompson D.A., and Lotze M.T. (Eds). The Cytokine Handbook (2004), Elsevier, London 603-625
49. Du Bois J.S., Trehu E.G., Mier J.W., Shapiro L., Epstein M., Klempner M., Dinarello C., Kappler K., Ronayne L., Rand W., and Atkins M.B. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptorimmunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol 15 (1997) 1052-1062
50. Elkordy M., Crump M., Vredenburgh J.J., Petros W.P., Hussein A., Rubin P., Ross M., Gilbert C., Modlin C., Meisenberg B., Coniglio D., Rabinowitz J., Laughlin M., Kurtzberg J., and Peters W.P. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant 19 (1997) 315-322
51. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., Leeb B., Breedveld F.C., Macfarlane J.D., Bijl H., and Woody J.N. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (1994) 1105-1110
52. Empl M., Renaud S., Erne B., Fuhr P., Straube A., Schaeren-Wiemers N., and Steck A.J. TNF-alpha expression in painful and nonpainful neuropathies. Neurology 56 (2001) 1371-1377
53. Empl M., Sostak P., Riedel M., Schwarz M., Muller N., Forderreuther S., and Straube A. Decreased sTNF-RI in migraine patients?. Cephalalgia 23 (2003) 55-58
54. Fan H., and Cook J.A. Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 10 (2004) 71-84
55. discussion 928-929. Fang P.K., Ma X.C., Ma D.L., and Fu K.Y. Determination of interleukin-1 receptor antagonist, interleukin-10, and transforming growth factor-beta1 in synovial fluid aspirates of patients withtemporomandibular disorders. J Oral Maxillofac Surg 57 (1999) 922-928
56. Fattori E., Cappelletti M., Costa P., Sellitto C., Cantoni L., Carelli M., Faggioni R., Fantuzzi G., Ghezzi P., and Poli V. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 180 (1994) 1243-1250
57. Fehrenbacher J.C., Burkey T.H., Nicol G.D., and Vasko M.R. Tumor necrosis factor alpha and interleukin-1beta stimulate the expression of cyclooxygenase II but do not alter prostaglandin E(2) receptor mRNAlevels in cultured dorsal root ganglia cells. Pain 113 (2005) 113-122
58. Ferreira S., Lorenzetti B., Bristow A., and Poole S. Interleukin-1β as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 334 (1988) 698-700
59. Fiorentino D.F., Bond M.W., and Mosmann T.R. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170 (1989) 2081-2095
60. Follenfant R.L., Nakamura-Craig M., Henderson B., and Higgs G.A. Inhibition by neuropeptides of interleukin-1 betainduced, prostaglandin-independent hyperalgesia. Br J Pharmacol 98 (1989) 41-43
61. Fraker D.L., and Alexander H.R. The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects. The NCI results. Melanoma Res 4 Suppl. 1 (1994) 27-29
62. Fu K., Ma X., Zhang Z., and Chen W. Tumor necrosis factor in synovial fluid of patients with temporomandibular disorders. J Oral Maxillofac Surg 53 (1995) 424-426
63. Fu K., Ma X., Zhang Z., Pang X., and Chen W. J Orofac Pain 9 (1995) 131-137
64. Fukuoka H., Kawatani M., Hisamitsu T., and Takeshige C. Cutaneous hyperalgesia induced by peripheral injection of interleukin-1β in the rat. Brain Res. 657 (1994) 133-140
65. Furman W.L., Luo X., Fairclough D., Garrison L., Marina N., Pratt C.B., Bleyer A., and Meyer W.H. Phase I trial of subcutaneous interleukin-1 alpha in children with malignant solid tumors. Med Pediatr Oncol 28 (1997) 444-450
66. Gao Y., Ng Y.K., Lin J.Y., and Ling E.A. Expression of immunoregulatory cytokines in neurons of the lateral hypothalamic area and amygdaloid nuclear complex of rats immunized againsthuman IgG. Brain Res 859 (2000) 364-368
67. Geiss A., Varadi E., Steinbach K., Bauer H.W., and Anton F. Psychoneuroimmunological correlates of persisting sciatic pain in patients who underwent discectomy. Neurosci Lett 237 (1997) 65-68
68. George A., Schmidt C., Weishaupt A., Toyka K.V., and Sommer C. Serial determination of tumor necrosis factor-alpha content in rat sciatic nerve after chronic constriction injury. Exp Neurol 160 (1999) 124-132
69. George A., Buehl A., and Sommer C. Wallerian degeneration after crush injury of rat sciatic nerve increases endo- and epineurial tumor necrosis factor-alpha protein. Neurosci Lett 372 (2004) 215-219
70. George A., Buehl A., and Sommer C. Tumor necrosis factor receptor 1 and 2 protein are differentially regulated during Wallerian degeneration of mouse sciatic nerve. Exp Neurol 192 (2005) 163-166
71. Glorioso J.C., and Fink D.J. Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Annu Rev Microbiol 58 (2004) 253-271
72. Gorman J.D., Sack K.E., and Davis Jr. J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346 (2002) 1349-1356
73. Gronblad M., Virri J., Tolonen J., Seitsalo S., Kaapa E., Kankare J., Myllynen P., and Karaharju E.O. A controlled immunohistochemical study of inflammatory cells in disc herniation tissue. Spine 19 (1994) 744-2751
74. Guida M., Abbate I., Casamassima A., Musci M.D., Latorre A., Lorusso V., Correale M., and De Lena M. Long-term subcutaneous recombinant interleukin-2 as maintenance therapy: biological effects and clinical implications. Cancer Biother 10 (1995) 195-203
75. Gul H., Yildiz O., Dogrul A., Yesilyurt O., and Isimer A. The interaction between IL-1beta and morphine: possible mechanism of the deficiency of morphine-induced analgesia in diabetic mice. Pain 89 (2000) 39-45
76. Gur A., Karakoc M., Nas K., Remzi, Cevik, Denli A., and Sarac J. Cytokines and depression in cases with fibromyalgia. J Rheumatol 29 (2002) 358-361
77. Hader N., Rimon D., Kinarty A., and Lahat N. Altered interleukin-2 secretion in patients with primary fibromyalgia syndrome. Arthritis Rheum 34 (1991) 866-872
78. Harrison J.K., Jiang Y., Chen S., Xia Y., Maciejewski D., McNamara R.K., Streit W.J., Salafranca M.N., Adhikari S., Thompson D.A., Botti P., Bacon K.B., and Feng L. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA 95 (1998) 10896-10901
79. Hatori K., Nagai A., Heisel R., Ryu J.K., and Kim S.U. Fractalkine and fractalkine receptors in human neurons and glial cells. J Neurosci Res 69 (2002) 418-426
80. Hattori A., Hayashi K., and Kohno M. Tumor necrosis factor (TNF) stimulates the production of nerve growth factor in fibroblasts via the 55-kDa type 1 TNF receptor. FEBS Lett 379 (1996) 157-160
81. Homma Y., Brull S.J., and Zhang J.M. A comparison of chronic pain behavior following local application of tumor necrosis factor alpha to the normal and mechanically compressed lumbarganglia in the rat. Pain 95 (2002) 239-246
82. Hulshof S., Montagne L., De Groot C.J., and Van Der Valk P. Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions. Glia 38 (2002) 24-35
83. Huygen F.J., De Bruijn A.G., De Bruin M.T., Groeneweg J.G., Klein J., and Zijistra F.J. Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm 11 (2002) 47-51
84. Huygen F.J., Niehof S., Zijlstra F.J., van Hagen P.M., and van Daele P.L. J Pain Symptom Manage 27 (2004) 101-103
85. Huygen F.J., Ramdhani N., Van Toorenenbergen A., Klein J., and Zijlstra F.J. Mast cells are involved in inflammatory reactions during complex regional pain syndrome type 1. Immunol Lett 91 (2004) 147-154
86. Igarashi T., Kikuchi S., Shubayev V., and Myers R.R. Volvo Award winner in basic science studies: exogenous tumor necrosis factor-alpha mimics nucleus pulposus-induced neuropathology. Molecular,histologic, and behavioral comparisons in rats. Spine 25 (2000) 2975-2980
87. Inoue A., Ikoma K., Morioka N., Kumagai K., Hashimoto T., Hide I., and Nakata Y. Interleukin-1beta induces substance P release from primary afferent neurons through the cyclooxygenase-2 system. J Neurochem 73: (1999) 2206-2213
88. Johnston I.N., Milligan E.D., Wieseler-Frank J., Frank M.G., Zapata V., Campisi J., Langer S., Martin D., Green P., Fleshner M., Leinwand L., Maier S.F., and Watkins L.R. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 24 (2004) 7353-7365
89. Joshi B.H., Leland P., Silber J., Kreitman R.J., Pastan I., Berger M., and Puri R.K. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-pseudomonas exotoxin fusion protein. Br J Cancer 86 (2002) 285-291
90. Junger H., and Sorkin L.S. Nociceptive and inflammatory effects of subcutaneous TNFalpha. Pain 85 (2000) 145-151
91. Kalso E., Edwards J.E., Moore R.A., and McQuay H.J. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 112 (2004) 372-380
92. Kaneyama K., Segami N., Nishimura M., Suzuki T., and Sato J. Importance of proinflammatory cytokines in synovial fluid from 121 joints with temporomandibular disorders. Br J Oral Maxillofac Surg 40 (2002) 418-423
93. Kaneyama K., Segami N., Nishimura M., Sato J., Fujimura K., and Yoshimura H. The ideal lavage volume for removing bradykinin, interleukin-6, and protein from the temporomandibular joint by arthrocentesis. J Oral Maxillofac Surg 62 (2004) 657-661
94. Kang J.D., Georgescu H.I., McIntyre-Larkin L., Stefanovic-Racic M., and Evans C.H. Herniated cervical intervertebral discs spontaneously produce matrix metalloproteinases, nitric oxide, interleukin-6, and prostaglandin E2. Spine 20 (1995) 2373-2378
95. Kariko K., Weissman D., and Welsh F.A. Inhibition of toll-like receptor and cytokine signaling-a unifying theme in ischemic tolerance. J Cereb Blood Flow Metab 24 (2004) 1288-1304
96. discussion 753-754. Karppinen J., Korhonen T., Malmivaara A., Paimela L., Kyllonen E., Lindgren K.A., Rantanen P., Tervonen O., Niinimaki J., Seitsalo S., and Hurri H. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. Spine 28 (2003) 750-753
97. Kemeny N., Childs B., Larchian W., Rosado K., and Kelsen D. A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer 66 (1990) 659-663
98. Kikuchi T., Nakamura T., Ikeda T., Ogata H., and Takagi K. Monocyte chemoattractant protein-1 in the intervertebral disc. A histologic experimental model. Spine 23 (1998) 1091-1099
99. Kim M.O., Suh H.S., Brosnan C.F., and Lee S.C. Regulation of RANTES/CCL5 expression in human astrocytes by interleukin-1 and interferon-beta. J Neurochem 90 (2004) 297-308
100. Kleinschnitz C., George A., Brinkhoff J., Zelenka M., Sommer C., and Stoll G. The extent of cytokine induction in peripheral nerve lesions depends on the mode of injury and NMDA receptor signaling. J Neuroimmunol 149 (2004) 77-83
101. Koch A.E., Kunkel S.L., and Strieter R.M. Cytokines in rheumatoid arthritis. J Invest Med 43 (1995) 28-38
102. Korhonen T., Karppinen J., Malmivaara A., Autio R., Niinimaki J., Paimela L., Kyllonen E., Lindgren K.A., Tervonen O., Seitsalo S., and Hurri H. Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up. Spine 29 (2004) 2115-2119
103. Kotani N., Kudo R., Sakurai Y., Sawamura D., Sessler D.I., Okada H., Nakayama H., Yamagata T., Yasujima M., and Matsuki A. Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia. Am J Med 116 (2004) 318-324
104. Kurzrock R., Feinberg B., Talpaz M., Saks S., and Gutterman J.U. Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients. J Interferon Res 9 (1989) 435-444
105. Lans T.E., Bartlett D.L., Libutti S.K., Gnant M.F., Liewehr D.J., Venzon D.J., Turner E.M., and Alexander H.R. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. Clin Cancer Res 7 (2001) 784-790
106. Leask A., and Abraham D.J. TGF-beta signaling and the fibrotic response. Faseb J 18 (2004) 816-827
107. Lee T.H., Avraham H., Lee S.H., and Avraham S. Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascularendothelial cells. J Biol Chem 277 (2002) 10445-10451
108. Lee Y.B., Nagai A., and Kim S.U. Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res 69 (2002) 94-103
109. Liao S.L., and Chen C.J. Differential effects of cytokines and redox potential on glutamate uptake in rat cortical glial cultures. Neurosci Lett 299 (2001) 113-116
110. Lienard D., Eggermont A.M., Koops H.S., Kroon B., Towse G., Hiemstra S., Schmitz P., Clarke J., Steinmann G., Rosenkaimer F., and Lejeune F.J. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of intransit melanomametastases: a multicentre randomized phase II study. Melanoma Res 9 (1999) 491-502
111. Lindenlaub T., Teuteberg P., Hartung T., and Sommer C. Effects of neutralizing antibodies to TNF-alpha on painrelated behavior and nerve regeneration in mice with chronic constriction injury. Brain Res 866 (2000) 15-22
112. Lindenlaub T., and Sommer C. Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol 105 (2003) 593-602
113. Lindholm D., Heumann R., Meyer M., and Thoenen H. Interleukin-1 regulates synthesis of nerve growth factor in nonneuronal cells of rat sciatic nerve. Nature 330 (1987) 658-659
114. Lobbezoo F., Drangsholt M., Peck C., Sato H., Kopp S., and Svensson P. Topical review: new insights into the pathology and diagnosis of disorders of the temporomandibular joint. J Orofac Pain 18 (2004) 181-191
115. Lorenzetti B.B., Poole S., Veiga F.H., Cunha F.Q., and Ferreira S.H. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-13. Eur Cytokine Netw 12 (2001) 260-267
116. Maes M., Libbrecht I., Van Hunsel F., Lin A.H., De Clerck L., Stevens W., Kenis G., de Jongh R., Bosmans E., and Neels H. The immune-inflammatory pathophysiology of fibromyalgia: increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines. Psychoneuroendocrinology 24 (1999) 371-383
117. Maier S.F., Wiertelak E.P., Martin D., and Watkins L.R. Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin. Brain Res 623 (1993) 321-324
118. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M., and Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitantmethotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
119. Mamet J., Baron A., Lazdunski M., and Voilley N. Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels. J Neurosci 22 (2002) 10662-10670
120. Mao J., Sung B., Ji R.R., and Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 22 (2002) 8312-8323
121. Mayer D.J., Mao J., Holt J., and Price D.D. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci USA 96 (1999) 7731-7736
122. Meller S.T., Dykstra C., Grzybycki D., Murphy S., and Gebhart G.F. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology 33 (1994) 1471-1478
123. Meucci O., Fatatis A., Simen A.A., and Miller R.J. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc Natl Acad Sci USA 97 (2000) 8075-8080
124. Mier J.W., Aronson F.R., Numerof R.P., Vachino G., and Atkins M.B. Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. Pathol Immunopathol Res 7 (1988) 459-476
125. Milligan E.D., Twining C., Chacur M., Biedenkapp J., O'Connor K., Poole S., Tracey K., Martin D., Maier S.F., and Watkins L.R. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 23 (2003) 1026-1040
126. Milligan E.D., Zapata V., Chacur M., Schoeniger D., Biedenkapp J., O'Connor K.A., Verge G.M., Chapman G., Green P., Foster A.C., Naeve G.S., Maier S.F., and Watkins L.R. Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur J Neurosci 20 (2004) 2294-2302
127. Miyagishi R., Kikuchi S., Takayama C., Inoue Y., and Tashiro K. Identification of cell types producing RANTES, MIP-1 alpha and MIP-1 beta in rat experimental autoimmune encephalomyelitis by in situ hybridization. J Neuroimmunol 77 (1997) 17-26
128. Mokhtarian F., Shi Y., Shirazian D., Morgante L., Miller A., and Grob D. Defective production of anti-inflammatory cytokine, TGF-beta by T cell lines of patients with active multiple sclerosis. J Immunol 152 (1994) 6003-6010
129. Moqbel R., Ying S., Barkans J., Newman T.M., Kimmitt P., Wakelin M., Taborda-Barata L., Meng Q., Corrigan C.J., Durham S.R., and Kay A.B. Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. J Immunol 155 (1995) 4939-4947
130. Moreland L.W., Schiff M.H., Baumgartner S.W., Tindall E.A., Fleischmann R.M., Bulpitt K.J., Weaver A.L., Keystone E.C., Furst D.E., Mease P.J., Ruderman E.M., Horwitz D.A., Arkfeld D.G., Garrison L., Burge D.J., Blosch C.M., Lange M.L., McDonnell N.D., and Weinblatt M.E. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130 (1999) 478-486
131. Morikawa O., Sakai N., Obara H., and Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 349 (1998) 317-324
132. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., and Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136 (1986) 2348-2357
133. Mössner R., Heils A., Stober G., Okladnova O., and Daniel S. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem Intl 33 (1998) 251-254
134. Mössner R., Daniel S., Schmitt A., Albert D., and Lesch K.P. Modulation of serotonin transporter function by interleukin-4. Life Sci 68 (2001) 873-880
135. Mueller L., Gupta A.K., and Stein T.P. Deficiency of tumor necrosis factor alpha in a subclass of menstrual migraineurs. Headache 41 (2001) 129-137
136. Mukaida N., Ketlinsky S.A., and Matsushima K. Interleukin-8 and other CXC chemokines. In: Thomson A.W., and Lotze M.T. (Eds). The Cytokine Handbook (2004), Elsevier, London 1047-1081
137. Munno I., Centonze V., Marinaro M., Bassi A., Lacedra G., Causarano V., Nardelli P., Cassiano M.A., and Albano O. Cytokines and migraine: increase of IL-5 and IL-4 plasma levels. Headache 38 (1998) 465-467
138. Munno I., Marinaro M., Bassi A., Cassiano M.A., Causarano V., and Centonze V. Immunological aspects in migraine: increase of IL-10 plasma levels during attack. Headache 41 (2001) 764-767
139. Murata Y., Onda A., Rydevik B., Takahashi K., and Olmarker K. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced histologic changes in the dorsal root ganglion. Spine 29 (2004) 2477-2484
140. Murphy P.G., Grondin J., Altares M., and Richardson P.M. Induction of interleukin-6 in axotomized sensory neurons. J Neurosci 15 (1995) 5130-5138
141. Murphy P.G., Ramer M.S., Borthwick L., Gauldie J., Richardson P.M., and Bisby M.A. Endogenous interleukin-6 contributes to hypersensitivity to cutaneous stimuli and changes in neuropeptides associated with chronic nerve constriction in mice. Eur J Neurosci 11 (1999) 2243-2253
142. Nakamura H., Nakanishi K., Kita A., and Kadokawa T. Interleukin-1 induces analgesia in mice by a central action. Eur J Pharmacol 149 (1988) 49-54
143. Nicol G.D., Lopshire J.C., and Pafford C.M. Tumor necrosis factor enhances the capsaicin sensitivity of rat sensory neurons. J Neurosci 17 (1997) 975-982
144. Nishiyori A., Minami M., Ohtani Y., Takami S., Yamamoto J., Kawaguchi N., Kume T., Akaike A., and Satoh M. Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia?. FEBS Lett 429 (1998) 167-172
145. Obreja O., Rathee P.K., Lips K.S., Distler C., and Kress M. IL-1 beta potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C. Faseb J 16 (2002) 1497-1503
146. Obreja O., Schmelz M., Poole S., and Kress M. Interleukin-6 in combination with its soluble IL-6 receptor sensitises rat skin nociceptors to heat, in vivo. Pain 96 (2002) 57-62
147. O'Brien S.M., Scott L.V., and Dinan T.G. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 19 (2004) 397-403
148. Ogura N., Tobe M., Sakamaki H., Nagura H., Hosaka H., Akiba M., Abiko Y., and Kondoh T. Interleukin-1 beta increases RANTES gene expression and production in synovial fibroblasts from human temporomandibular joint. J Oral Pathol Med 33 (2004) 629-633
149. Oh S.B., Tran P.B., Gillard S.E., Hurley R.W., Hammond D.L., and Miller R.J. Chemokines and glycoprotein 120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci 21 (2001) 5027-5035
150. Oka T., Aou S., and Hori T. Intracerebroventricular injection of interleukin-1β induces hyperalgesia in rats. Brain Res 624 (1993) 61-68
151. Oka T., Aou S., and Hori T. Intracerebroventricular injection of interleukin-1 beta enhances nociceptive neuronal responses of the trigeminal nucleus caudalis in rats. Brain Res 656 (1994) 236-244
152. Oka T., Oka K., Hosoi M., and Hori T. Intracerebroventricular injection of interleukin-6 induces thermal hyperalgesia in rats. Brain Res 692 (1995) 123-128
153. Oka T., Wakugawa Y., Hosoi M., Oka K., and Hori T. Intracerebroventricular injection of tumor necrosis factor-alpha induces thermal hyperalgesia in rats. Neuroimmunomodulation 3 (1996) 135-140
154. Okada H., Banchereau J., and Lotze M.T. Interleukin-4. In: Thompson D.A., and Lotze M.T. (Eds). The Cytokine Handbook (2004), Elsevier, London 227-262
155. Olmarker K., Rydevik B., and Nordborg C. Autologous nucleus pulposus induces neurophysiologic and histologic changes in porcine cauda equina nerve roots. Spine 18 (1993) 1425-1432
156. Olmarker K., and Larsson K. Tumor necrosis factor alpha and nucleus-pulposus-induced nerve root injury. Spine 23 (1998) 2538-2544
157. Olmarker K., and Rydevik B. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerveconduction velocity: possible implications for future pharmacologic treatment strategies of sciatica. Spine 26 (2001) 863-869
158. discussion. Olmarker K., Nutu M., and Storkson R. Changes in spontaneous behavior in rats exposed to experimental disc herniation are blocked by selective TNF-alpha inhibition. Spine 28 (2003) 1635-1641
159. Olmarker K., Nutu M., and Storkson R. Changes in spontaneous behavior in rats exposed to experimental disc herniation are blocked by selective TNF-alpha inhibition. Spine 28 (2003) 1642
160. Omer F.M., de Souza J.B., Corran P.H., Sultan A.A., and Riley E.M. Activation of transforming growth factor beta by malaria parasite-derived metalloproteinases and a thrombospondin-like molecule. J Exp Med 198 (2003) 1817-1827
161. Onda A., Yabuki S., and Kikuchi S. Effects of neutralizing antibodies to tumor necrosis factor-alpha on nucleus pulposus-induced abnormal nociresponses in rat dorsal horn neurons. Spine 28 (2003) 967-972
162. Opree A., and Kress M. Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, IL-1beta, and IL-6 but not IL-8 in the development of heat hyperalgesia:effects on heat-evoked calcitonin gene-related peptide release from rat skin. J Neurosci 20 (2000) 6289-6293
163. Ozaktay A.C., Cavanaugh J.M., Asik I., DeLeo J.A., and Weinstein J.N. Dorsal root sensitivity to interleukin-1 beta, interleukin-6 and tumor necrosis factor in rats. Eur Spine J 11 (2002) 467-475
164. Perkins M.N., Kelly D., and Davis A.J. Bradykinin B1 and B2 receptor mechanisms and cytokine-induced hyperalgesia in the rat. Can J Physiol Pharmacol 73 (1995) 832-836
165. Pitt D., Nagelmeier I.E., Wilson H.C., and Raine C.S. Glutamate uptake by oligodendrocytes: implications for excitotoxicity in multiple sclerosis. Neurology 61 (2003) 1113-1120
166. Pollock J., McFarlane S.M., Connell M.C., Zehavi U., Vandenabeele P., MacEwan D.J., and Scott R.H. TNF-alpha receptors simultaneously activate Ca2+ mobilisation and stress kinases in cultured sensory neurones. Neuropharmacology 42 (2002) 93-106
167. Poole S., Cunha F.Q., Selkirk S., Lorenzetti B.B., and Ferreira S.H. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10. Br J Pharmacol 115 (1995) 684-688
168. Poole S., Cunha F.Q., and Ferreira S.H. Hyperalgesia from subcutaneous cytokines. In: Watkins L.R., and Maier S.F. (Eds). Cytokines and Pain (1999), Birkhäuser, Basel 59-87
169. Raghavendra V., Rutkowski M.D., and DeLeo J.A. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci 22 (2002) 9980-9989
170. Raghavendra V., Tanga F., and DeLeo J.A. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther 306 (2003) 624-630
171. Raghavendra V., Tanga F.Y., and DeLeo J.A. Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci 20 (2004) 467-473
172. Rainero I., Grimaldi L.M., Salani G., Valfre W., Rivoiro C., Savi L., and Pinessi L. Association between the tumor necrosis factor-alpha-308 G/A gene polymorphism and migraine. Neurology 62 (2004) 141-143
173. Ramer M.S., Murphy P.G., Richardson P.M., and Bisby M.A. Spinal nerve lesion-induced mechanoallodynia and adrenergic sprouting in sensory ganglia are attenuated in interleukin-6 knockout mice. Pain 78 (1998) 115-121
174. Rankin E.C., Choy E.H., Kassimos D., Kingsley G.H., Sopwith A.M., Isenberg D.A., and Panayi G.S. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 34 (1995) 334-342
175. Reynolds J.L., Ignatowski T.A., Sud R., and Spengler R.N. Brain-derived tumor necrosis factor-alpha and its involvement in noradrenergic neuron functioning involved in the mechanism of action of anantidepressant. J Pharmacol Exp Ther 310 (2004) 1216-1225
176. Ribeiro R.A., Vale M.L., Ferreira S.H., and Cunha F.Q. Analgesic effect of thalidomide on inflammatory pain. Eur J Pharmacol 391 (2000) 97-103
177. Ridderstad A., Abedi-Valugerdi M., and Moller E. Cytokines in rheumatoid arthritis. Ann Med 23 (1991) 219-223
178. Rutkowski J.L., Tuite G.F., Lincoln P.M., Boyer P.J., Tennekoon G.I., and Kunkel S.L. Signals for proinflammatory cytokine secretion by human Schwann cells. J Neuroimmunol 101 (1999) 47-60
179. Sachs D., Cunha F.Q., Poole S., and Ferreira S.H. Tumour necrosis factor-alpha, interleukin-1beta and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. Pain 96 (2002) 89-97
180. Safieh-Garabedian B., Poole S., Allchorne A., Winter J., and Woolf C.J. Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol 115 (1995) 1265-1275.
181. Salemi S., Rethage J., Wollina U., Michel B.A., Gay R.E., Gay S., and Sprott H. Detection of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol 30 (2003) 146-150
182. Samad T.A., Moore K.A., Sapirstein A., Billet S., Allchorne A., Poole S., Bonventre J.V., and Woolf C.J. Interleukin-1betamediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410 (2001) 471-475
183. discussion. Sandler N.A., Buckley M.J., Cillo J.E., and Braun T.W. Correlation of inflammatory cytokines with arthroscopic findings in patients with temporomandibular joint internal derangements. J Oral Maxillofac Surg 56 (1998) 534-543
184. Sandler N.A., Buckley M.J., Cillo J.E., and Braun T.W. Correlation of inflammatory cytokines with arthroscopic findings in patients with temporomandibular joint internal derangements. J Oral Maxillofac Surg 56 (1998) 543-544
185. Sarno E.N., Grau G.E., Vieira L.M., and Nery J.A. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp Immunol 84 (1991) 103-108
186. Schäfers M., Brinkhoff J., Neukirchen S., Marziniak M., and Sommer C. Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor-alpha and interleukin-1 receptor has an additive effect in reducing neuropat. Neurosci Lett 310 (2001) 113-116
187. Schäfers M., Geis C., Brors D., Yaksh T.L., and Sommer C. Anterograde transport of tumor necrosis factor-alpha in the intact and injured rat sciatic nerve. J Neurosci 22 (2002) 536-545
188. Schäfers M., Geis C., Svensson C.I., Luo Z.D., and Sommer C. Selective increase of tumour necrosis factor-alpha in injured and spared myelinated primary afferents after chronic constrictive injury of rat sciatic nerve. Eur J Neurosci 17 (2003) 791-804
189. Schäfers M., Lee D.H., Brors D., Yaksh T.L., and Sorkin L.S. Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligation. J Neurosci 23 (2003) 3028-3038
190. Schäfers M., Sorkin L.S., Geis C., and Shubayev V.I. Spinal nerve ligation induces transient upregulation of tumor necrosis factor receptors 1 and 2 in injured and adjacent uninjured dorsal root ganglia in the r. Neurosci Lett 347 (2003) 179-182
191. Schäfers M., Sorkin L.S., and Sommer C. Intramuscular injection of tumor necrosis factor-alpha induces muscle hyperalgesia in rats. Pain 104 (2003) 579-588
192. Schäfers M., Svensson C.I., Sommer C., and Sorkin L.S. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 23 (2003) 2517-2521
193. 2004. Schäfers M., Marziniak M., Sorkin L.S., Yaksh T.L., and Sommer C. Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat. Exp Neurol 185 (2004) 160-168
194. Schall T.J., Bacon K., Toy K.J., and Goeddel D.V. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347 (1990) 669-671
195. Schiller J.H., Storer B.E., Witt P.L., Alberti D., Tombes M.B., Arzoomanian R., Proctor R.A., McCarthy D., Brown R.R., and Voss S.D. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. Cancer Res 51 (1991) 1651-1658
196. Schweizer A., Feige U., Fontana A., Muller K., and Dinarello C.A. Interleukin-1 enhances pain reflexes. Mediation through increased prostaglandin E2 levels. Agents Actions 25 (1988) 246-251
197. discussion. Shafer D.M., Assael L., White L.B., and Rossomando E.F. Tumor necrosis factor-alpha as a biochemical marker of pain and outcome in temporomandibular joints with internal derangements. J Oral Maxillofac Surg 52 (1994) 786-791
198. Shafer D.M., Assael L., White L.B., and Rossomando E.F. Tumor necrosis factor-alpha as a biochemical marker of pain and outcome in temporomandibular joints with internal derangements. J Oral Maxillofac Surg 52 (1994) 791-792
199. Shen Y.Q., Hebert G., Lin L.Y., Luo Y.L., Moze E., Li K.S., and Neveu P.J. Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization. J Neuroimmunol 158 (2005) 14-25
200. Shubayev V.I., and Myers R.R. Upregulation and interaction of TNFalpha and gelatinases A and B in painful peripheral nerve injury. Brain Res 855 (2000) 83-89
201. Shubayev V.I., and Myers R.R. Axonal transport of TNFalpha in painful neuropathy: distribution of ligand tracer and TNF receptors. J Neuroimmunol 114 (2001) 48-56
202. Shukaliak J.A., and Dorovini-Zis K. Expression of the beta-chemokines RANTES and MIP-1 beta by human brain microvessel endothelial cells in primary culture. J Neuropathol Exp Neurol 59 (2000) 339-352
203. Smith E.M., Cadet P., Stefano G.B., Opp M.R., and Hughes Jr. T.K. IL-10 as a mediator in the HPA axis and brain. J Neuroimmunol 100 (1999) 140-148
204. Solovieva S., Leino-Arjas P., Saarela J., Luoma K., Raininko R., and Riihimaki H. Possible association of interleukin 1 gene locus polymorphisms with low back pain. Pain 109 (2004) 8-19
205. Sommer C. Cytokines and neuropathic pain. In: Hansson P., Fields H., Hill R., and Marchettini P. (Eds). Neuropathic Pain: Pathophysiology and Treatment (2001), IASP Press, Seattle, WA 37-62
206. Sommer C., Schmidt C., George A., and Toyka K.V. A metalloprotease-inhibitor reduces pain associated behavior in mice with experimental neuropathy. Neurosci Lett 237 (1997) 45-48
207. Sommer C., Marziniak M., and Myers R.R. The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Pain 74 (1998) 83-91
208. Sommer C., Schmidt C., and George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp Neurol 151 (1998) 138-142
209. Sommer C., Petrausch S., Lindenlaub T., and Toyka K.V. Neutralizing antibodies to interleukin 1-receptor reduce pain associated behavior in mice with experimental neuropathy. Neurosci Lett 270 (1999) 25-28
210. Sommer C., Lindenlaub T., Teuteberg P., Schafers M., Hartung T., and Toyka K.V. Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res 913 (2001) 86-89
211. Sommer C., Schäfers M., Marziniak M., and Toyka K.V. Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst 6 (2001) 67-72
212. Song P., and Zhao Z.Q. The involvement of glial cells in the development of morphine tolerance. Neurosci Res 39 (2001) 281-286
213. Sorkin L.S., Xiao W.H., Wagner R., and Myers R.R. Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 81 (1997) 255-262
214. Spriggs D.R., Sherman M.L., Michie H., Arthur K.A., Imamura K., Wilmore D., Frei III E., and Kufe D.W. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 80 (1988) 1039-1044
215. Stark B., Carlstedt T., and Risling M. Distribution of TGFbeta, the TGF-beta type I receptor and the R-II receptor in peripheral nerves and mechanoreceptors; observations on changes after traumatic. Brain Res 913 (2001) 47-56
216. Stefano G.B., Salzet B., and Fricchione G.L. Enkelytin and opioid peptide association in invertebrates and vertebrates: immune activation and pain. Immunol Today 19 (1998) 265-268
217. Sweitzer S., Martin D., and DeLeo J.A. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience 103 (2001) 529-539
218. Takahashi H., Suguro T., Okazima Y., Motegi M., Okada Y., and Kakiuchi T. Inflammatory cytokines in the herniated disc of the lumbar spine. Spine 21 (1996) 218-224
219. Tanaka T., Minami M., Nakagawa T., and Satoh M. Enhanced production of monocyte chemoattractant protein-1 in the dorsal root ganglia in a rat model of neuropathic pain: possible involvement in thedevelopment of neuropathic pain. Neurosci Res 48 (2004) 463-469.
220. Taskinen H.S., Olsson T., Bucht A., Khademi M., Svelander L., and Roytta M. Peripheral nerve injury induces endoneurial expression of IFN-gamma, IL-10 and TNF-alpha mRNA. J Neuroimmunol 102 (2000) 17-25
221. Tha K.K., Okuma Y., Miyazaki H., Murayama T., Uehara T., Hatakeyama R., Hayashi Y., and Nomura Y. Changes in expressions of proinflammatory cytokines IL-1beta, TNF-alpha and IL-6 in the brain of senescence accelerated mouse (SAM) P8. Brain Res 885 (2000) 25-31
222. Tilg H., Atkins M.B., Dinarello C.A., and Mier J.W. Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapy. Cytokine 7 (1995) 734-739
223. Tobe M., Ogura N., Abiko Y., and Nagura H. Interleukin-1beta stimulates interleukin-8 production and gene expression in synovial cells from human temporomandibular joint. J Oral Maxillofac Surg 60 (2002) 741-747
224. Tobinick E.L., and Britschgi-Davoodifar S. Perispinal TNF-alpha inhibition for discogenic pain. Swiss Med Wkly 133 (2003) 170-177
225. Tofaris G.K., Patterson P.H., Jessen K.R., and Mirsky R. Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in aprocess regulated by interleukin-6 and LIF. J Neurosci 22 (2002) 6696-6703
226. Tominaga K., Habu M., Sukedai M., Hirota Y., Takahashi T., and Fukuda J. IL-1 beta, IL-1 receptor antagonist and soluble type II IL-1 receptor in synovial fluid of patients with temporomandibular disorders. Arch Oral Biol 49 (2004) 493-499
227. Tsuchida K. Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metabol Disord 4 (2004) 157-166
228. Program No. 863.10. Üceyler N., Valenza R., Sprotte G., and Sommer C. Fibromyalgia and cytokine expression under IVIG treatment. 2004 Abstract Viewer/Itinerary Planner (2004), Society for Neuroscience, Washington DC
229. Unsicker K., and Strelau J. Functions of transforming growth factor-beta isoforms in the nervous system. Cues based on localization and experimental in vitro and in vivo evidence. Eur J Biochem 267 (2000) 6972-6975
230. Vale M.L., Marques J.B., Moreira C.A., Rocha F.A., Ferreira S.H., Poole S., Cunha F.Q., and Ribeiro R.A. Antinociceptive effects of interleukin-4, -10, and -13 on the writhing response in mice and zymosan-induced knee joint incapacitation in rats. J Pharmacol Exp Ther 304 (2003) 102-108
231. van de Beek W.J., Remarque E.J., Westendorp R.G., and van Hilten J.J. Innate cytokine profile in patients with complex regional pain syndrome is normal. Pain 91 (2001) 259-261
232. Van Doorn P.A., and Ruts L. Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Opin Neurol 17 (2004) 607-613
233. Van Wagoner N.J., and Benveniste E.N. Interleukin-6 expression and regulation in astrocytes. J Neuroimmunol 100 (1999) 124-139
234. Velazquez J.R., Lacy P., Mahmudi-Azer S., Bablitz B., Milne C.D., Denburg J.A., and Moqbel R. Interleukin-4 and RANTES expression in maturing eosinophils derived from human cord blood CD34+ progenitors. Immunology 101 (2000) 419-425
235. Verge G.M., Milligan E.D., Maier S.F., Watkins L.R., Naeve G.S., and Foster A.C. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci 20 (2004) 1150-1160
236. Vitkovic L., Bockaert J., and Jacque C. "Inflammatory" cytokines: neuromodulators in normal brain?. J Neurochem 74 (2000) 457-471
237. Vogel C., Lindenlaub T., Tiegs G., Toyka K.V., and Sommer C. Pain related behavior in TNF-receptor deficient mice. In: Devor M., Rowbotham M.C., and Wiesenfeld-Hallin Z. (Eds). Proceedings of the 9th World Congress on Pain, Progress in Pain Research and Management (2000), IASP Press, Seattle, WA 249-257
238. Wagner R., Janjigian M., and Myers R.R. Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-alpha expression. Pain 74 (1998) 35-42
239. Wallace D.J., Linker-Israeli M., Hallegua D., Silverman S., Silver D., and Weisman M.H. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 40 (2001) 743-749
240. Wang Z., Pekarskaya O., Bencheikh M., Chao W., Gelbard H.A., Ghorpade A., Rothstein J.D., and Volsky D.J. Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120. Virology 312 (2003) 60-73
241. Watkins L.R., Wiertelak E.P., Goehler L.E., Smith K.P., Martin D., and Maier S.F. Characterization of cytokine-induced hyperalgesia. Brain Res 654 (1994) 15-26
242. Watkins L.R., Maier S.F., and Goehler L.E. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain 63 (1995) 289-302
243. Wehling P. Transfer of genes to intervertebral disc cells: proposal for a treatment strategy of spinal disorders by local gene therapy. Joint Bone Spine 68 (2001) 554-556
244. Weinblatt M.E., Keystone E.E., Furst D.E., Moreland C.W., Weisman M.H., Birbara C.A., Theo L.A., Fischkoff S.A., and Chartash E.K. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients takingconcomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (2003) 35-45
245. Wieseler-Frank J., Maier S.F., and Watkins L.R. Glial activation and pathological pain. Neurochem Intl 45 (2004) 389-395
246. Winkelstein B.A., Rutkowski M.D., Sweitzer S.M., Pahl J.L., and DeLeo J.A. Nerve injury proximal or distal to the DRG induces similar spinal glial activation and selective cytokine expression but differential behavioralresponses to pharmacologic treatment. J Comp Neurol 439 (2001) 127-139
247. Woolf C.J., Allchorne A., Safieh-Garabedian B., and Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol 121 (1997) 417-424
248. Xu X.J., Hao J.X., Andell-Jonsson S., Poli V., Bartfai T., and Wiesenfeld-Hallin Z. Nociceptive responses in interleukin-6-deficient mice to peripheral inflammation and peripheral nerve section. Cytokine 9 (1997) 1028-1033
249. Yirmiya R., Pollak Y., Morag M., Reichenberg A., Barak O., Avitsur R., Shavit Y., Ovadia H., Weidenfeld J., Morag A., Newman M.E., and Pollmacher T. Illness, cytokines, and depression. Ann NY Acad Sci 917 (2000) 478-487
250. Yoshimura T., Matsushima K., Oppenheim J.J., and Leonard E.J. Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization andseparation from interleukin 1 (IL 1). J Immunol 139 (1987) 788-793
251. Zak-Prelich M., McKenzie R.C., Sysa-Jedrzejowska A., and Norval M. Local immune responses and systemic cytokine responses in zoster: relationship to the development of postherpetic neuralgia. Clin Exp Immunol 131 (2003) 318-323
252. Zelenka M., Schafers M., and Sommer C. Intraneural injection of interleukin-1beta and tumour necrosis factoralpha into rat sciatic nerve at physiological doses induces signs of neuropathic pain. Pain 116 (2005) 257-263
253. Zhang J.M., Li H., Liu B., and Brull S.J. Acute topical application of tumor necrosis factor alpha evokes protein kinase A-dependent responses in rat sensory neurons. J Neurophysiol 88 (2002) 1387-1392
254. Zhang N., Rogers T.J., Caterina M., and Oppenheim J.J. Proinflammatory chemokines, such as C-C chemokine ligand 3, desensitize mu-opioid receptors on dorsal root ganglia neurons. J Immunol 173 (2004) 594-599
255. Zhong J., Dietzel I.D., Wahle P., Kopf M., and Heumann R. Sensory impairments and delayed regeneration of sensory axons in interleukin-6-deficient mice. J Neurosci 19 (1999) 4305-4313